Advancing bio-printing of living cells for regenerative medicine

Overview

Supports the development and clinical translation of advanced bio-printing technologies for regenerative medicine, targeting researchers, SMEs, and healthcare providers aiming to create high-cell-density bio-constructs for human tissue repair or organ regeneration.

Who Can Apply

Consortia of legal entities, including universities, research institutions, SMEs, healthcare providers, and industry partners. Entities from the United States are also eligible for funding. Participation of SMEs is encouraged.

Funding Details

Maximum grant amount: €12,000,000 per project. Funding rate and co-funding requirements are not specified.

What Is Funded

• Development or improvement of bio-printing equipment for high-cell-density constructs to enhance vascularisation and defect repair.
• Scaling bio-printing technologies to Good Manufacturing Practices (GMP) compliance.
• Regulatory work and first-in-human clinical studies to assess clinical value.
• Approaches targeting vital internal organs (via surgical grafting) or in-situ bio-printing for direct defect repair.
• Preclinical and clinical development across any therapeutic area, with consideration of sex differences at the cellular level.

Technology / Maturity Requirements

Projects must operate at Technology Readiness Levels (TRL) 7–9.

Key Dates

• Open date: 2027-06-02
• Deadline: 2027-09-21

Application Process (High-Level)

Single-stage submission via the EU Funding & Tenders Portal. Applicants are strongly encouraged to use the provided clinical studies template in the submission system.

Post-Award Obligations

• Compliance with EU regulatory frameworks for Substances of Human Origin (SoHO), medical devices, and Advanced Therapy Medicinal Products (ATMPs).
• The granting authority may object to transfers of ownership or exclusive licensing of results for up to four years post-project.

Geographic Scope & Language

Eligible countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Norway, Iceland, United Kingdom, Switzerland. Application language: English.

Notes

• Proposals must include multidisciplinary teams (engineers, biomedical scientists, cell biologists, medical doctors).
• Priority given to projects addressing internal organs or in-situ bio-printing.
• Use of Copernicus and/or Galileo/EGNOS is mandatory if satellite-based data/services are employed.
• The Joint Research Centre (JRC) may participate as a zero-funding beneficiary or associated partner.